Equine Peripheral Gene Expression Changes in Response to Dose-Dependent Lipopolysaccharide-Induced Synovitis.
Authors: Page Allen E, Wood Courtney, Partridge Emma, Horohov David W, Adam Emma
Journal: Journal of equine veterinary science
Summary
# Editorial Summary: Equine Peripheral Gene Expression Changes in Response to Dose-Dependent Lipopolysaccharide-Induced Synovitis Researchers sought to establish a controlled model of acute joint inflammation in horses that would generate measurable systemic immune responses whilst maintaining manageable clinical signs, thereby enabling future evaluation of anti-inflammatory therapies. Three geldings received intra-articular lipopolysaccharide injections into alternating carpal joints across a range of doses (1–1,000 ng), with blood sampling and lameness assessment conducted at multiple time points to measure changes in 23 gene expressions, complete blood cell counts, and serum amyloid A concentrations. The study confirmed dose-dependent upregulation of key inflammatory markers—notably CD14, TLR4, IL-1β, IL1RN, MMP1 and MMP9—alongside elevated acute phase responses; however, attempts to identify a threshold dose that would provoke robust gene expression without severe lameness proved unsuccessful, as doses of 10 ng or higher consistently produced non-weight-bearing lameness whilst 1 ng triggered neither detectable clinical nor molecular response. These findings have important implications for practitioners designing equine research protocols: whilst the LPS synovitis model reliably reproduces inflammatory biomarker changes relevant to naturally occurring joint disease, the narrow therapeutic window between negligible and severe clinical effects may limit its utility for testing new anti-inflammatory interventions in a way that reflects practical treatment scenarios. Future refinement of dosing strategies or injection sites may be necessary to bridge this gap and create a clinically applicable research platform.
Read the full abstract on PubMed
Practical Takeaways
- •This model demonstrates the challenge of inducing measurable systemic inflammatory responses while maintaining rideability—doses producing sufficient mRNA changes cause severe lameness unsuitable for treatment trials
- •The dose-dependent relationship (10ng+ causes nonweight-bearing lameness, 1ng shows no effect) establishes thresholds that may inform future anti-inflammatory treatment studies in joint inflammation models
- •Peripheral blood gene expression (CD14, TLR4, IL-1β, MMP1/9) responds sensitively to intra-articular LPS and could serve as biomarkers for monitoring treatment efficacy in experimental inflammation protocols
Key Findings
- •LPS doses of 10ng or higher induced nonweight-bearing lameness, while 1ng dose produced neither detectable lameness nor significant mRNA expression changes
- •Multiple genes showed significant upregulation during acute inflammation including CD14, TLR4, IL-1β, IL1RN, MMP1, and MMP9
- •Dose-dependent changes in gene expression were observed in response to varying LPS concentrations
- •Serum amyloid A concentrations and complete blood cell count parameters significantly increased following LPS injection